Joint Formulary & PAD

Formulary Search

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Search

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A-Z of Drugs

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Atopic dermatitis (Pimecrolimus - Atopic dermatitis)

Records returned : 8 (on 04 Sep 2025 at 04:55:06). Return to search results for ' Atopic dermatitis '.

Show Icon and Status Keys

Drug
Indication
Status
Restrictions/Comments
Formulary Status
Links
Indication :
Status :
Blue
Formulations :
  • Cream
Restrictions / Comments:

Important

Specialist iniation and first supply only by physicians (including general practitioners) with a special interest and experience in dermatology, and only after careful discussion with the patient about the potential risks and benefits of all appropriate second-line treatment options.

 
Links :
Indication :
Status :
Blue
Formulations :
  • Ointment
Restrictions / Comments:

Important

Specialist iniation and first supply only by physicians (including general practitioners) with a special interest and experience in dermatology, and only after careful discussion with the patient about the potential risks and benefits of all appropriate second-line treatment options.

 
Links :
Indication :
Status :
Red
Formulations :
  • Tablets
Restrictions / Comments:

Important

MHRA risk JAK inhibitors - see PAD for details.

 
Links :
Indication :
Status :
Red
Formulations :
  • Tablets
Restrictions / Comments:

Important

MHRA risk JAK inhibitors - see PAD for details.

 
Links :
Indication :
Status :
Red
Formulations :
  • Subcutaneous injection (sc)
Restrictions / Comments:

 
Links :
Indication :
Status :
Red
Formulations :
  • Subcutaneous injection (sc)
Restrictions / Comments:

 
Links :
Indication :
Status :
Red
Formulations :
  • Subcutaneous injection (sc)
Restrictions / Comments:

 
Links :
Indication :
Status :
Red
Formulations :
  • Tablets
Restrictions / Comments:

Important

MHRA risk JAK inhibitors - see PAD for details.

 
Links :